In April 2019, after a long-fought effort, including hospital litigation against the government, the Health Resources and Services Administration (HRSA) began posting 340B ceiling prices on its website and finalized regulations that would impose … [Read more...]

In the past 18 months, the 340B drug contract pharmacy program has seemingly fractured into 17 programs, one governed by the federal government and 16 others with their own standards determined by pharmaceutical manufacturers. Frustrated by program … [Read more...]

With the recent decision in AstraZeneca's lawsuit against the federal government on the legality of the 340B contract pharmacy program, we have reached an inflection point. Federal judges have now ruled on the first six lawsuits filed by drug … [Read more...]

It's hard to believe that election season is around the corner. But in less than a year, Congress could look ve­­­ry different than it does now. All signs foretell a Republican takeover of the House and a very good possibility of the GOP assuming … [Read more...]

It is always risky to make predictions, particularly about federal policy, the courthouse, and politics. Nonetheless, in the spirit of the New Year, here are three predictions in the 340B drug pricing area for 2022: … [Read more...]

In this month's column, I am going to touch upon the flurry of recent court decisions in the 340B contract pharmacy standoff and then dive into a key argument made by each of the pharmaceutical manufacturers in their suits against the government. … [Read more...]

After a quiet period, the pharmaceutical industry and its congressional allies are renewing efforts to make long-sought changes to the 340B program. While the moves are unlikely to gain much traction in a Democratically controlled Congress and White … [Read more...]

As of publication time, eight pharmaceutical manufacturers either have stopped offering or placed significant restrictions on 340B discounts when a provider contracts with a retail or community pharmacy to dispense medicines. After the Health … [Read more...]

Imagine if there was a way to resolve two of the most intractable challenges in the 340B program in one fell swoop: one that has a significant impact on the financial health of 340B providers, and another that affects the pharmaceutical industry’s … [Read more...]

As we get closer to the one-year mark since a group of drug manufacturers stopped offering 340B discounts or placed restrictions on these discounts in the contract pharmacy setting, several unanswered questions remain. Here are four burning ones: … [Read more...]